

**PATENT**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:	)	
	)	
David Sidransky <i>et al.</i>	)	
	)	Group Art Unit: TBA
Application Serial No.: TBA	)	
	)	Examiner: TBA
Filed: April 8, 2004	)	
	)	
For: BRAF MUTATION T1796A IN THYROID	)	
CANCERS	)	Atty. Docket No.: 001107.00463

**INFORMATION DISCLOSURE STATEMENT**


Commissioner for Patents  
Post Office Box 1450  
Alexandria, Virginia 22313-1450

Dear Sir:

Dear Sir:

Submitted herewith is two (2) sheets of Form PTO-1449. A copy of each of the references listed therein is enclosed. It is respectfully requested that the Examiner make his/her consideration of each of these documents formally of record.

Since this Information Disclosure Statement is being filed before issuance of a first Office Action on the merits under 37 C.F.R. 1.97(b), it is submitted that no fee or certification is required. However, if a fee is required, please charge our deposit account no. 19-0733.

Respectfully submitted,  
  
By: \_\_\_\_\_  
Sarah A. Kagan  
Registration No. 32,141

Dated: April 9, 2004

Banner & Witcoff, Ltd.  
Customer No. 22907

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Application Number	TBA
				Filing Date	
				First Named Inventor	David Sidransky
				Art Unit	TBA
				Examiner Name	TBA
Sheet	1	of	2	Attorney Docket Number	001107.00463

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		WEBER <i>et al.</i> , "Active Ras Induces Heterodimerization of cRaf and Brf1", <i>Cancer Research</i> , May 1, 2001, pp. 3595-3598, Vol. 61.	
		HOGREFE R., "An Antisense Oligonucleotide Primer", <i>Antisense and Nucleic Acid Drug Development</i> , 1999, Table 1 updated 2002, pp. 351-357, Vol. 9.	
		WILHELM <i>et al.</i> , "BAY 43-9006: Preclinical Data", <i>Current Pharmaceutical Design</i> , 2002, pp. 2255-2257, Vol. 8.	
		COHEN <i>et al.</i> , "BRAF Mutation in Papillary Thyroid Carcinoma", <i>Journal of the National Cancer Institute</i> , April 16, 2003, pp. 625-627, Vol. 95, No. 8.	
		NAMBA <i>et al.</i> , "Clinical Implication of Hot Spot BRAF Mutation, V599E, in Papillary Thyroid Cancers", <i>The Journal of Clinical Endocrinology &amp; Metabolism</i> , 2003, pp. 4393-4397, Vol. 88(9).	
		HUANG <i>et al.</i> , "Gene Expression in Papillary Thyroid Carcinoma Reveals Highly Consistent Profiles", <i>Proceedings of the National Academy of Sciences</i> , December 18, 2001, pp. 15044-15049, Vol. 98, No. 26.	
		KIMURA <i>et al.</i> , "High Prevalence of BRAF Mutations in Thyroid Cancer: Genetic Evidence for Constitutive Activation of the RET/PTC-RAS-BRAF Signaling Pathway in Papillary Thyroid Carcinoma", <i>Cancer Research</i> , April 1, 2003, pp. 1454-1457, Vol. 63.	
		DAUM <i>et al.</i> , "The Ins and Outs of Raf Kinases", <i>Elsevier Science Ltd.</i> , November 1994, pp. 474-480.	
		DAVIES <i>et al.</i> , "Mutations of the BRAF Gene in Human Cancer", <i>Nature</i> , June 27, 2002, pp. 949-954, Vol. 417.	
		CRIPPS <i>et al.</i> , "Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Locally Advanced or Metastatic Colorectal Cancer: A National Cancer Institute of Canada Clinical Trials Group Study <sup>1</sup> ", <i>Clinical Cancer Research</i> , July 2002, pp. 2188-2192, Vol. 8.	
		YIN <i>et al.</i> , "RNA-mediated Gene Regulation System: Now and the Future (Review)", <i>International Journal of Molecular Medicine</i> , 2002, pp. 355-365, Vol. 10.	
		COLLISSON <i>et al.</i> , "Treatment of Metastatic Melanoma with an Orally Available Inhibitor of the Ras-Raf-MAPK Cascade <sup>1,2</sup> ", <i>Cancer Research</i> , September 15, 2003, pp. 5669-5673, Vol. 63.	
		KOLCH <i>et al.</i> , "Animation of the Organisation and Function of the Ras-Raf-MEK-ERK Pathway", Expert Reviews in Molecular Medicine: <a href="http://www.expertreviews.org">http://www.expertreviews.org</a> , Accession Information: (02)00444-1h.htm (shortcode: swf001 wkq); 14 August 2002 (Abstract only)	
		MULLEN <i>et al.</i> , "Antisense Oligonucleotide Targeting of raf-1: Importance of Raf-1 mRNA Expression Levels and Raf-1-Dependent Signaling in Determining Growth Response in Ovarian Cancer", <i>Clinical Cancer Research</i> , March 15, 2004, pp. 2100-8, Vol. 10(6). (Abstract only)	

Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(use as many sheets as necessary)*

Sheet	2
-------	---

of 2

**Complete if Known**

Application Number

**TBA**

Filing Date

First Named Inventor

**David Sidransky**

**Art Unit**

**TBA**

**Examiner Name**

**TBA**

Attorney Docket Number

001107.00463

[illegible]

Examiner  
Signature

Date \_\_\_\_\_

Considered

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

**If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.**